Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cyclopharm Limited ( (AU:CYC) ) has provided an update.
Cyclopharm Limited has appointed Thomas Lukas as Vice President of Sales in the United States to lead a new Business Development Team, aiming to accelerate sales of Technegas in the U.S. market. This strategic hire is part of Cyclopharm’s multi-stage U.S. sales strategy, which includes expanding their sales operations and increasing the adoption of Technegas across U.S. hospital systems. The company is capitalizing on the growing awareness of Technegas’ clinical value, supported by established reimbursement and federal engagements, as well as strong clinical advocacy.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community. The company focuses on improving patient care outcomes through its core product, Technegas®, which is used for functional lung ventilation imaging.
Average Trading Volume: 74,748
Technical Sentiment Signal: Sell
Current Market Cap: A$116.1M
Learn more about CYC stock on TipRanks’ Stock Analysis page.